 |
|
|
|
February 2000 Cover
|
|
A new study from researchers at the Johns Hopkins University School of Medicine shows that 10 percent of HIV patients taking protease inhibitor Norvir are
experiencing severe liver problems. The team studied 298 HIV patients in Baltimore, more than half of whom were co-infected with hepatitis C. After about six months of
follow-up, 26 of 211 patients receiving protease inhibitors had developed severe liver toxicity, which can lead to liver failure. Patients on Norvir were more likely to have
liver toxicity compared to other protease inhibitors, at a rate of 30 percent to 7 percent.
Editor's Note: from JAMA
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
